Padhi D, Jang G, Stouch B et al (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26

Article  CAS  Google Scholar 

Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427

Article  CAS  Google Scholar 

McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420

Article  CAS  Google Scholar 

Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585–1594

Article  CAS  Google Scholar 

Genant HK, Engelke K, Bolognese MA et al (2017) Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32:181–187

Article  CAS  Google Scholar 

Lewiecki EM, Blicharski T, Goemaere S et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183–3193

Article  Google Scholar 

Gregson CL, Armstrong DJ, Bowden J et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17:58

Article  Google Scholar 

Shoback D, Rosen CJ, Black DM, et al (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105:. https://doi.org/10.1210/clinem/dgaa048

Chen Z, Li M, Li S et al (2023) A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab. Expert Opin Drug Saf 22:339–342

Article  CAS  Google Scholar 

Vestergaard Kvist A, Faruque J, Vallejo-Yagüe E, et al (2021) Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med Res 10:. https://doi.org/10.3390/jcm10081660

Kotake K, Mitsuboshi S, Omori Y et al (2023) Evaluation of risk of cardiac or cerebrovascular events in romosozumab users focusing on comorbidities: analysis of the Japanese Adverse Drug Event Report Database. J Pharm Technol 39:23–28

Article  CAS  Google Scholar 

Reyes C, Pottegård A, Schwarz P et al (2016) Real-life and RCT participants: alendronate users versus FITs’ trial eligibility criterion. Calcif Tissue Int 99:243–249

Article  CAS  Google Scholar 

Inose H, Ariga A, Motoyoshi T et al (2022) The real-world effect of 12 months of romosozumab treatment on patients with osteoporosis with a high risk of fracture and factors predicting the rate of bone mass increase: a multicenter retrospective study. JBMR Plus 6:e10637

Article  CAS  Google Scholar 

Kobayakawa T, Suzuki T, Nakano M et al (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep 14:101068

Article  CAS  Google Scholar 

Okada A, Yasunaga H (2022) Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J 5:190–198

Google Scholar 

Masuda S, Fukasawa T, Takeuchi M et al (2024) Are dental procedures associated with pyogenic vertebral osteomyelitis? Clin Orthop Relat Res 482:716–723

Article  Google Scholar 

Shigemi D, Okada A, Yasunaga H (2023) Postoperative adverse events and re-treatment among patients who have undergone laparoscopic and robotic sacrocolpopexy for pelvic organ prolapse in Japan. Int J Gynaecol Obstet 161:114–119

Article  Google Scholar 

Yoshida K, Solomon DH, Kim SC (2015) Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 11:437–441

Article  CAS  Google Scholar 

Kim SC, Solomon DH, Rogers JR et al (2017) Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol 69:1154–1164

Article  CAS  Google Scholar 

Schneeweiss S, Rassen JA, Brown JS et al (2019) Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med 170:398–406

Article  Google Scholar 

Stürmer T, Wang T, Golightly YM et al (2020) Methodological considerations when analysing and interpreting real-world data. Rheumatology 59:14–25

Article  Google Scholar 

Wright NC, Daigle SG, Melton ME et al (2019) The design and validation of a new algorithm to identify incident fractures in administrative claims data. J Bone Miner Res 34:1798–1807

Article  Google Scholar 

Lyu H, Yoshida K, Zhao SS et al (2020) Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study. Ann Intern Med 173:516–526

Article  Google Scholar 

Sing C-W, Woo Y-C, Lee ACH et al (2017) Validity of major osteoporotic fracture diagnosis codes in the Clinical Data Analysis and Reporting System in Hong Kong. Pharmacoepidemiol Drug Saf 26:973–976

Article  Google Scholar 

Leslie WD, Epp R, Morin SN, Lix LM (2021) Assessment of site-specific X-ray procedure codes for fracture ascertainment: a registry-based cohort study. Arch Osteoporos 16:107

Article  Google Scholar 

Fujihara K, Yamada-Harada M, Matsubayashi Y et al (2021) Accuracy of Japanese claims data in identifying diabetes-related complications. Pharmacoepidemiol Drug Saf 30:594–601

Article  Google Scholar 

Ritchey MD, Loustalot F, Wall HK et al (2017) Million hearts: description of the national surveillance and modeling methodology used to monitor the number of cardiovascular events prevented during 2012–2016. J Am Heart Assoc 6:e006021

Article  Google Scholar 

Zheng Y, Fukasawa T, Yamaguchi F et al (2024) Cardiovascular safety of atomoxetine and methylphenidate in patients with attention-deficit/hyperactivity disorder in japan: a self-controlled case series study. J Atten Disord 28:439–450

Article  Google Scholar 

Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427

Article  Google Scholar 

Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682

Article  Google Scholar 

Cosman F, Cooper C, Wang Y et al (2022) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int 33:1703–1714

Article  CAS  Google Scholar 

Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397

Article  CAS  Google Scholar 

Ebina K, Etani Y, Tsuboi H et al (2022) Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int 33:1807–1813

Article  CAS  Google Scholar 

Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34:3661–3679

Article  Google Scholar 

Desai RJ, Franklin JM (2019) Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 367:l5657

Article  Google Scholar 

Xu S, Ross C, Raebel MA et al (2010) Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13:273–277

Article  Google Scholar 

Austin PC (2009) Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat - Simul Comput 38:1228–1234

Article  Google Scholar 

Schneeweiss S, Gagne JJ, Glynn RJ et al (2011) Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 90:777–790

Article  CAS  Google Scholar 

Tan EH, Rathod-Mistry T, Strauss VY et al (2024) Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases. J Bone Miner Res 39:844–854

Article  Google Scholar 

Axelsson KF, Nilsson AG, Wedel H et al (2017) Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 318:146–155

Article  CAS  Google Scholar 

Händel MN, Cardoso I, von Bülow C et al (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ 381:e068033

Article  Google Scholar 

Arlot M, Meunier PJ, Boivin G et al (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244–1253